Key result
Implantable loop recorders in pediatric patients with inherited arrhythmia syndromes yielded actionable data in 7% of transmissions, leading to escalated therapies in 30% of subjects.
Why the study?
Does implantable loop recorder monitoring improve management in pediatric patients with inherited arrhythmia syndromes?
Observational (n=20)
Does implantable loop recorder monitoring improve management in pediatric patients with inherited arrhythmia syndromes?
Implantable loop recorders in pediatric patients with inherited arrhythmia syndromes can effectively guide management, leading to therapy escalation in 30% of patients and providing reassurance during benign symptomatic events.
BACKGROUND: Implantable loop recorders (ILRs) are conventionally utilized to elucidate the mechanism of atypical syncope. The objective of this study was to assess the impact of these devices on management of pediatric patients with known or suspected inherited arrhythmia syndromes. METHODS AND RESULTS: A retrospective chart review was undertaken of all pediatric patients with known or suspected inherited arrhythmia syndromes in whom an ILR was implanted from 2008 to 2015. Captured data included categorization of diagnosis, treatment, transmitted tracings, and the impact of ILR tracings on management. Transmissions were categorized as symptomatic, autotriggered, or routine. Actionable transmissions were abnormal tracings that directly resulted in a change of medical or device therapy. A total of 20 patients met the stated inclusion criteria (long QT syndrome, n=8, catecholaminergic polymorphic ventricular tachycardia,n=9, Brugada syndrome, n=1, arrhythmogenic right ventricular cardiomyopathy, n=2), with 60% of patients being genotype positive. Primary indication for implantation of ILR included ongoing monitoring +/- symptoms (n=15, 75%), suspicion of noncompliance (n=1, 5%), and liberalization of recommended activity restrictions (n=4, 25%). A total of 172 transmissions were received in patients with inherited arrhythmia syndromes, with 7% yielding actionable data. The majority (52%) of symptom events were documented in the long QT syndrome population, with only 1 tracing (5%) yielding actionable data. Automatic transmissions were mostly seen in the catecholaminergic polymorphic ventricular tachycardia cohort (81%), with 21% yielding actionable data. There was no actionable data in routine transmissions. CONCLUSIONS: ILRs in patients with suspected or confirmed inherited arrhythmia syndromes may be useful for guiding management. Findings escalated therapies in 30% of subjects. As importantly, in this high-risk population, the majority of symptom events represented normal or benign rhythms, reassuring patients and physicians that no further intervention was required.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2016) conducted an observational in Inherited arrhythmia syndromes (n=20). Implantable loop recorders was evaluated on Escalation of therapies based on actionable transmissions. Implantable loop recorders in pediatric patients with inherited arrhythmia syndromes yielded actionable data in 7% of transmissions, leading to escalated therapies in 30% of subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: